Crinetics Pharmaceuticals, Inc. 8-K Filing
Ticker: CRNX · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1658247
| Field | Detail |
|---|---|
| Company | Crinetics Pharmaceuticals, Inc. (CRNX) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Pages | 5 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $577,000, $15,000, $6,500, $600 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Crinetics Pharmaceuticals, Inc. (ticker: CRNX) to the SEC on Dec 17, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select Mar); $577,000 (receive cash severance in the amount of $577,000, which is an amount equal to twelve mon); $15,000 (Transition Agreement in an amount up to $15,000, to reimburse Dr. Pizzuti for monthly C); $6,500 (t training course in an amount of up to $6,500. The foregoing payments shall be payabl); $600 (r. Pizzuti will receive compensation of $600 per hour as well as reimbursement for r).
How long is this filing?
Crinetics Pharmaceuticals, Inc.'s 8-K filing is 5 pages with approximately 1,364 words. Estimated reading time is 5 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,364 words · 5 min read · ~5 pages · Grade level 11.8 · Accepted 2025-12-17 17:00:04
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CRNX Nasdaq Global Select Mar
- $577,000 — receive cash severance in the amount of $577,000, which is an amount equal to twelve mon
- $15,000 — Transition Agreement in an amount up to $15,000, to reimburse Dr. Pizzuti for monthly C
- $6,500 — t training course in an amount of up to $6,500. The foregoing payments shall be payabl
- $600 — r. Pizzuti will receive compensation of $600 per hour as well as reimbursement for r
Filing Documents
- crnx-20251216.htm (8-K) — 32KB
- exhibit101transitionsepara.htm (EX-10.1) — 69KB
- exhibit102advisoragreement.htm (EX-10.2) — 80KB
- 0001658247-25-000022.txt ( ) — 329KB
- crnx-20251216.xsd (EX-101.SCH) — 2KB
- crnx-20251216_lab.xml (EX-101.LAB) — 21KB
- crnx-20251216_pre.xml (EX-101.PRE) — 12KB
- crnx-20251216_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Transition and Separation Agreement, dated as of December 16, 2025, between Crinetics Pharmaceuticals, Inc. and Dana Pizzuti. 10.2 Advisor Agreement, dated December 16, 2025, between Crinetics Pharmaceuticals, Inc. and Dana Pizzuti. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Crinetics Pharmaceuticals, Inc. Date: December 17, 2025 By: /s/ R. Scott Struthers, Ph.D. R. Scott Struthers, Ph.D. President and Chief Executive Officer (Principal Executive Officer)